Company intelligence / Profile preview

Fusion Pharmaceuticals Inc.

Hamilton, Ontario, Canadaprnewswire.com ↗

Ownership: Public · FUSN
Development stage: Phase 2

Overview

Lead program FPI-2265 is in Phase 2 trials for metastatic castration-resistant prostate cancer. The company has developed a platform for targeted alpha therapeutics with proprietary Fast-Clear™ linker technology.

Therapeutic areas: Oncology
Modalities: Targeted Alpha Therapeutics (TATs)Radioconjugates (RCs)
Industry: Biotech

Drug pipeline

3 assets

FPI-2265

Phase 2

Indications: Metastatic castration-resistant prostate cancer

2 more assets in the full pipeline.

Request access →

Partnerships

AstraZenecaMerck (for evaluating FPI-1434 in combination with KEYTRUDA®)TRIUMFNiowave Inc.BWXT Medical Ltd. (for actinium supply)

Beyond the preview

Go deeper on Fusion Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fusion Pharmaceuticals Inc..

Explore the full profile